Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| RNA | PRESS-RELEASE | neutral | 2/10 | Atrium Therapeutics granted stock options and RSUs to one newly hired non-executive employee as an inducement under Nasd | Jul 20, 2026 |
| TLX | PRESS-RELEASE | bullish | 4/10 | Telix Pharmaceuticals announced the first patient dosed in its Phase 3 LUTEON1 trial evaluating TLX250-Tx, a CAIX-target | Jul 20, 2026 |
| TOMZ | PRESS-RELEASE | neutral | 3/10 | TOMI Environmental Solutions issued a press release providing an update on Carbonium Core's business, referencing the pr | Jul 20, 2026 |
| PHAT | PRESS-RELEASE | neutral | 1/10 | Phathom Pharmaceuticals announced it will report its Q2 2026 results on July 30, 2026. | Jul 20, 2026 |
| EIKN | PRESS-RELEASE | neutral | 3/10 | Eikon Therapeutics announced that seven abstracts covering its pipeline (EIK1001, EIK1003, EIK1004, EIK1005) have been a | Jul 20, 2026 |
| OKYO | PRESS-RELEASE | bullish | 5/10 | OKYO Pharma filed its annual report and provided a corporate update highlighting a $22M capital raise, $20.6M cash posit | Jul 20, 2026 |
| HROW | PRESS-RELEASE | neutral | 5/10 | Harrow presented three studies at ASRS 2026 supporting IHEEZO and BYOOVIZ, including interim randomized data suggesting | Jul 20, 2026 |
| FDMT | PRESS-RELEASE | bullish | 6/10 | 4D Molecular Therapeutics announced positive 2-year data from the PRISM Phase 2b trial of 4D-150 in wet AMD, showing 78% | Jul 18, 2026 |
| CATX | PRESS-RELEASE | neutral | 4/10 | Perspective Therapeutics announced that updated data from its [212Pb]VMT-α-NET program for neuroendocrine tumors has bee | Jul 17, 2026 |
| CMPX | PRESS-RELEASE | bullish | 6/10 | Compass Therapeutics announces that its Phase 2/3 COMPANION-002 trial of tovecimig + paclitaxel in advanced biliary trac | Jul 17, 2026 |
| CNTN | PRESS-RELEASE | neutral | 3/10 | Canton Strategic Holdings issued a Q2 2026 ecosystem report on the Canton Network, highlighting governance milestones an | Jul 17, 2026 |
| AMRX | PRESS-RELEASE | bullish | 6/10 | Amneal received FDA approval for additional strengths and vial presentations of iohexol injection, a generic version of | Jul 17, 2026 |
| EVAX | PRESS-RELEASE | neutral | 4/10 | Evaxion will present three-year Phase 2 data for personalized cancer vaccine EVX-01 at ESMO 2026 (Oct 23-27). The third- | Jul 17, 2026 |
| RGNX | PRESS-RELEASE | bearish | 7/10 | REGENXBIO priced a $100M underwritten public offering of 10M shares at $9.00/share plus 1.1M pre-funded warrants, repres | Jul 17, 2026 |
| KLRS | PRESS-RELEASE | bullish | 6/10 | Kalaris Therapeutics reported positive additional Phase 1a SAD data for TH103 in neovascular AMD, showing improved durab | Jul 17, 2026 |
| JSPR | PRESS-RELEASE | mixed | 8/10 | Jasper Therapeutics acquired Kira Pharmaceuticals in an all-stock transaction, concurrent with a $132M private placement | Jul 16, 2026 |
| ARTL | PRESS-RELEASE | neutral | 4/10 | Artelo Biosciences announced new preclinical data for ART26.12, its FABP5 inhibitor, showing efficacy comparable to napr | Jul 16, 2026 |
| VCEL | PRESS-RELEASE | neutral | 1/10 | Vericel Corporation announced it will report its Q2 2026 results on July 30, 2026. | Jul 16, 2026 |
| PTCT | PRESS-RELEASE | neutral | 1/10 | PTC Therapeutics, Inc. announced it will report its Q2 2026 results on July 30, 2026. | Jul 16, 2026 |
| GRFS | PRESS-RELEASE | neutral | 4/10 | Grifols announced first patient dosing in two Phase 3 trials (SIGMA and XPERT) seeking U.S. label expansion for its immu | Jul 16, 2026 |
| QUCY | PRESS-RELEASE | neutral | 4/10 | Quantum Cyber announced $2.09M in purchase orders at its subsidiary Quantum Drones Corporation, received as part of the | Jul 16, 2026 |
| BCTXL | PRESS-RELEASE | neutral | 3/10 | BriaCell announced that Sunnybrook's Odette Cancer Centre has joined its pivotal Phase 3 study of Bria-IMT plus an immun | Jul 16, 2026 |
| MDCX | PRESS-RELEASE | bullish | 5/10 | Medicus Pharma received FDA feedback and central IRB approval for its optimized Phase 2 study of Teverelix in men with a | Jul 16, 2026 |
| ZYME | PRESS-RELEASE | neutral | 1/10 | Zymeworks Inc. announced it will report its Q2 2026 results on August 6, 2026. | Jul 16, 2026 |
| ARGX | PRESS-RELEASE | neutral | 1/10 | argenx SE announced it will report its Q2 2026 results on July 23, 2026. | Jul 16, 2026 |
| MOLN | PRESS-RELEASE | neutral | 4/10 | Molecular Partners announced dosing of first patients in a Phase 2 proof-of-concept study (TACTIC) of MP0317 combined wi | Jul 16, 2026 |
| TLX | PRESS-RELEASE | neutral | 4/10 | Telix Pharmaceuticals announced first patient dosing in the Phase 2 OPTIMAL-e trial evaluating TLX597-Tx for metastatic | Jul 15, 2026 |
| SPRC | PRESS-RELEASE | bullish | 5/10 | SciSparc subsidiary NeuroThera Labs initiated a Phase IIb clinical trial site at Hannover Medical School for SCI-110, a | Jul 15, 2026 |
| RANI | PRESS-RELEASE | bullish | 7/10 | Rani Therapeutics reported positive initial Phase 1a data for RT-114, an oral RaniPill® capsule delivering a GLP-1/GLP-2 | Jul 15, 2026 |
| TPST | PRESS-RELEASE | bullish | 6/10 | Tempest Therapeutics announced its next-generation in vivo CAR-T platform and plans to advance lead candidate TPST-4003 | Jul 15, 2026 |